Treace Medical Concepts, Inc. (TMCI) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents mixed signals: while revenue and adjusted EBITDA show improvement, the net loss has increased, and the core Lapiplasty business is facing challenges due to shifting preferences towards minimally invasive procedures. Additionally, management's refusal to provide 2026 guidance and reliance on general optimism without specifics raises concerns. The decrease in gross margin and increased operating expenses further contribute to a negative sentiment, despite progress in profitability and liquidity management.
Key Financial Performance
Revenue $50.2 million in Q3 2025, an increase of $5.1 million or 11% year-over-year. Growth was mainly driven by an increase in bunion procedure kits sold compared to the prior year.
Gross Margin 79.1% in Q3 2025 compared to 80.1% in Q3 2024, a slight decrease due to changes in product mix and other factors.
Operating Expenses $55.4 million in Q3 2025, an increase of 8% compared to $51.3 million in Q3 2024. The increase reflects higher medical education, surgeon training events, restructuring charges, and litigation expenses.
Net Loss $16.3 million or $0.26 per share in Q3 2025, an increase of 6% compared to $15.4 million or $0.25 per share in Q3 2024. The increase was due to higher operating expenses.
Adjusted EBITDA Loss $2.6 million in Q3 2025, a reduction of 49% compared to $5.1 million in Q3 2024. This improvement reflects progress towards profitability goals.
Year-to-Date Net Loss $49.6 million in 2025, a decrease of 10% compared to $55.2 million in 2024. The improvement was driven by better cost management and operational efficiencies.
Year-to-Date Adjusted EBITDA Loss $10.1 million in 2025, a decrease of 54% compared to $22.1 million in 2024. This reflects significant progress in improving profitability.
Total Liquidity $80.6 million as of September 30, 2025, compared to $90.7 million at the end of Q2 2025. The decrease was due to operational cash usage, though cash usage decreased year-over-year by 17% in Q3 and 58% year-to-date.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Bunion Correction Systems: Developed and commercialized 3 new bunion correction systems, expanding the product portfolio to address 100% of surgeon preferences for bunion correction.
Lapiplasty Lightning Platform: Introduced next-generation instrumentation to increase precision and speed of Lapiplasty 3D correction.
Percuplasty Compression Screw System: Launched a new line of compression screw implants to complement the SpeedPlate platform.
Market Share Expansion: Broadened customer base by attracting surgeons who prefer metatarsal osteotomy procedures and expanded relationships with existing customers.
Distributor Strategy: Entered into stocking relationships with key distributors, resulting in $6 million in stocking distributor sales in Q3.
Revenue Growth: Achieved $50.2 million in Q3 revenue, an 11% increase from the prior year.
Cost Management: Reduced adjusted EBITDA loss by 49% in Q3 and decreased cash usage by 17% in Q3 and 58% year-to-date.
Strategic Shift to Comprehensive Solutions: Transitioned from a single technology company to a comprehensive bunion solutions provider, leveraging a broader product portfolio.
Focus on Profitability: Implemented cost control measures and focused on improving profitability and reducing cash burn for 2026.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Growth: The company experienced slower-than-expected revenue growth, with a revised outlook of only 1%-2% growth for 2025 compared to 2024. This is attributed to economic conditions, softer consumer sentiment, and a shift in product mix.
Product Mix Shift: There is a shift in sales from higher ASP (Average Selling Price) Lapiplasty systems to lower ASP bunion systems, which impacts overall revenue levels.
Economic Conditions: Broader economic conditions and softer consumer sentiment are leading to deferrals of elective bunion procedures, particularly for commercially insured patients.
Distributor Sales Timing: The company benefited from a one-time increase in sales to stocking distributors in Q3, which is not expected to recur at the same levels in Q4, creating a headwind for future quarters.
Surgeon and Patient Preferences: Surgeons and patients are shifting preferences towards minimally invasive osteotomies, which is impacting the adoption of the company's flagship Lapiplasty system.
Adoption of New Products: While new products are gaining traction, the adoption rate is not yet sufficient to offset pressures on the Lapiplasty line.
Operating Expenses: Operating expenses increased by 8% year-over-year, driven by medical education, surgeon training events, restructuring charges, and increased litigation expenses.
Profitability Challenges: Despite improvements in adjusted EBITDA, the company is still operating at a loss, with a net loss of $16.3 million in Q3 2025.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: The company revised its full-year 2025 revenue guidance to a range of $211 million to $213 million, representing growth of 1% to 2% compared to full-year 2024.
Profitability and Adjusted EBITDA: The company expects a loss in adjusted EBITDA in the range of $6.5 million to $7.5 million for the full year 2025, reflecting a 32% to 41% improvement over the prior year. Additionally, cash use is expected to decrease by 43% to 47% for the full year 2025 compared to 2024.
Market Trends and Consumer Sentiment: The company is experiencing headwinds from broader economic conditions and softer consumer sentiment, leading to deferrals of elective bunion procedures. A survey indicated a 7% decrease in bunion surgical volumes year-to-date through October 2025 compared to the same period last year.
Product Portfolio and Market Share: The company plans to continue training its 3,100+ current customers on new systems and focus on adding new surgeon customers. Over 20% of surgeon customers have adopted one or more of the new bunion technologies within one quarter of launch. The company expects increased adoption of its portfolio to drive market share gains and expand procedure volumes.
Innovation Pipeline: The company plans to deliver a robust pipeline of new innovations expected to impact 2026, including the Lapiplasty Lightning platform, Percuplasty compression screw system, and new SpeedPlate implants. These innovations aim to enhance precision, speed, and procedural opportunities.
Sales Strategy and Leadership: The company plans to strengthen its sales team by adding experienced foot and ankle sales professionals and leveraging new commercial and sales leadership to improve productivity and impact in 2026 and beyond.
Cost Structure and Profitability: The company is taking actions to control its organizational cost structure, aiming to improve profitability, adjusted EBITDA, and reduce cash burn in 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk a bit more about the softness in the core Lapiplasty business and how you're thinking about that trending from here? If there is a growing preference for MIS osteotomy, do you think this is something that can turn around eventually? What could get this to return to growth if doctor preferences have just been shifting elsewhere?
A:John Treace explained that while there is a trend towards minimally invasive osteotomies, the Lapiplasty market remains relevant for severe or unstable bunion deformities. The company is capturing market share in the minimally invasive osteotomy and MTP fusion markets, but at a lower price point. They aim to bring more surgeons into the Lapiplasty domain using new product technology, though current gains are not enough to offset the overall softness.
Q:What does the current guidance imply for fourth quarter sales, and how should we think about the first few quarters of 2026?
A:Mark Hair stated that they are not providing guidance for 2026 at this time and will update during the Q4 earnings call. He highlighted optimism due to increased case volumes in Q3 and anticipated growth in Q4, driven by new bunion systems and upcoming innovations.
Q:Has there been an acceleration in the shift away from Lapiplasty, and can the sales team accelerate the adoption of new bunion technologies to offset this shift?
A:John Treace acknowledged the trend towards minimally invasive procedures and highlighted their novel technologies like Percuplasty and Nanoplasty. The sales team is focusing on these new products to drive penetration and engagement, which could eventually lead to top-line growth.
Q:What actions are being taken to control costs and find efficiencies on the P&L?
A:Mark Hair mentioned ongoing efforts to control costs, including a restructuring charge in Q3 and evaluating further cost structure changes. He emphasized their scalable business model, high margins, and focus on improving profitability.
Q:How do you plan to recoup deferred procedures going into next year, and what are the qualitative factors for 2026?
A:John Treace stated that they aim to capture a larger share of patients by leveraging new products, improving consumer sentiment, and enhancing sales team engagement. He expressed confidence in their ability to attract more patients for surgeries next year.
Q:Review of Unclear Management Responses
A:Management avoided providing specific guidance for 2026, instead deferring updates to the Q4 earnings call. Their responses lacked quantitative details and relied on general optimism about case volume growth, new product adoption, and cost control measures.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ability
adoption
ankle sale
audience
bunion system
bunion technology
case volume
compression screw
condition consumer
consumer sentiment
date loss
decrease loss
design
director
distributor partner
dynamic outlook
headwind
implant
investorstreacecom
leader
loss decrease
loss period
market dynamic
mix
number
opportunity surgeon
portfolio product
position market
pressure
product portfolio
relationship
result outlook
segment
stocking
surgeon preference
system sale
system surgeon
training event
volume surgeon
TMCI Transcript
Treace Medical Concepts, Inc. (TMCI) Q1 2026 Earnings Call Transcript
Unknown5-8
Despite a decline in revenue and widening losses, the company has demonstrated effective cash management and cost reduction. The upcoming product launches and market expansion plans could positively impact future growth. However, persistent ASP headwinds and competitive pressures present risks. The Q&A session revealed mixed sentiments, with management providing optimistic guidance but avoiding specifics on market penetration. Given the balance of positive and negative factors, the stock price is likely to remain stable in the near term, resulting in a neutral sentiment.
Treace Medical Concepts, Inc. (TMCI) Q4 2025 Earnings Call Transcript
Unknown2-27
The earnings call reveals mixed signals. While the company shows improved financial health, with reduced losses and cash use, and has a strong product pipeline, the market is facing softness and uncertainties. Although there is optimism about new product adoption and sales force expansion, the guidance remains cautious, reflecting macroeconomic headwinds. Furthermore, management's lack of clarity on long-term growth rates adds to uncertainty. The positive aspects are balanced by potential risks, leading to a neutral sentiment.
Treace Medical Concepts, Inc. (TMCI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
Treace Medical Concepts, Inc. (TMCI) Q3 2025 Earnings Call Transcript
Unknown11-7
The earnings call presents mixed signals: while revenue and adjusted EBITDA show improvement, the net loss has increased, and the core Lapiplasty business is facing challenges due to shifting preferences towards minimally invasive procedures. Additionally, management's refusal to provide 2026 guidance and reliance on general optimism without specifics raises concerns. The decrease in gross margin and increased operating expenses further contribute to a negative sentiment, despite progress in profitability and liquidity management.
TMCI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
